Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement
Open Access
- 15 April 2004
- journal article
- research article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 379 (2) , 497-503
- https://doi.org/10.1042/bj20031596
Abstract
Coagulation Factor VIIa (FVIIa) lacks the ability to spontaneously complete the conversion to a fully active enzyme after specific cleavage of an internal peptide bond (Arg152–Ile153) in the zymogen. Recently, several variants of FVIIa with enhanced intrinsic activity have been constructed. The in vitro characterization of these variants has shed light on molecular determinants that put restrictions on FVIIa in favour of a zymogen-like conformation and warrants continued efforts. Here we describe a new FVIIa variant with high intrinsic activity containing the mutations Leu305→Val, Ser314→Glu, Lys337→Ala, and Phe374→Tyr. The variant, called FVIIaVEAY, processes a tripeptidyl substrate very efficiently because of an unprecedented, 5.5-fold lowering of the Km value. Together with a 4-fold higher substrate turnover rate this gives the variant a catalytic efficiency 22 times that of wild-type FVIIa, which is reflected in a considerably enhanced susceptibility to inhibition by antithrombin and other inhibitors. For instance, the affinity of FVIIaVEAY for the S1 probe and inhibitor p-aminobenzamidine is represented by an 8-fold lower Ki value compared with that of FVIIa. Activation of Factor X in solution occurs about 10 times faster with FVIIaVEAY than with FVIIa, due virtually exclusively to an increased kcat value. The high activity of FVIIaVEAY is not accompanied by an increased burial of the N-terminus of the protease domain. A comparison of the kinetic parameters and molecular properties of FVIIaVEAY with those of the previously described mutant V158D/E296V/M298Q-FVIIa (FVIIaIIa), and the locations of the substitutions in the two variants, reveals what appear to be two profoundly different structural mechanisms dictating improvements in enzymic performance.Keywords
This publication has 33 references indexed in Scilit:
- Assignment of molecular properties of a superactive coagulation factor VIIa variant to individual amino acid changesPublished by Wiley ,2002
- Platelets and Thrombin GenerationArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Residue Met156 Contributes to the Labile Enzyme Conformation of Coagulation Factor VIIaJournal of Biological Chemistry, 2001
- Role of Residue Phe225 in the Cofactor-Mediated, Allosteric Regulation of the Serine Protease Coagulation Factor VIIaBiochemistry, 2000
- Allosteric Regulation of the Cofactor-Dependent Serine Protease Coagulation Factor VIIaTrends in Cardiovascular Medicine, 1998
- Structural changes in factor VIIa induced by Ca2+ and tissue factor studied using circular dichroism spectroscopyProtein Science, 1996
- Influence of the γ-Carboxyglutamic Acid-Rich Domain and Hydrophobic Stack of Factor Vila on Tissue Factor BindingPathophysiology of Haemostasis and Thrombosis, 1996
- Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism.Journal of Biological Chemistry, 1993
- Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent autoactivation of human coagulation factor VIIBiochemistry, 1991
- Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation.Proceedings of the National Academy of Sciences, 1988